90 related articles for article (PubMed ID: 25030993)
1. Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma.
Shin DY; Kim S; Park S; Koh JS; Kim CH; Baek H; Yang SH; Na II
Endocr Relat Cancer; 2014 Oct; 21(5):715-21. PubMed ID: 25030993
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
3. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.
Jin B; Dong Y; Wang HM; Huang JS; Han BH
Acta Pharmacol Sin; 2014 Mar; 35(3):373-80. PubMed ID: 24487967
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
5. Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
Fujimoto D; Tomii K; Otoshi T; Kawamura T; Tamai K; Takeshita J; Tanaka K; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Hata A; Tachikawa R; Otsuka K; Hamakawa H; Katakami N; Takahashi Y; Imai Y
Lung Cancer; 2013 May; 80(2):159-64. PubMed ID: 23419507
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma.
Matsumura Y; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Hoshino M; Osugi J; Higuchi M; Suzuki H
Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):690-695. PubMed ID: 29049789
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
[TBL] [Abstract][Full Text] [Related]
9. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.
Hsu JS; Huang MS; Chen CY; Liu GC; Liu TC; Chong IW; Chou SH; Yang CJ
J Thorac Imaging; 2014 Nov; 29(6):357-63. PubMed ID: 25303964
[TBL] [Abstract][Full Text] [Related]
10. Associations of serum 25-hydroxyvitamin D level with incidence of lung cancer and histologic types in Norwegian adults: a case-cohort analysis of the HUNT study.
Sun YQ; Langhammer A; Wu C; Skorpen F; Chen Y; Nilsen TIL; Romundstad PR; Mai XM
Eur J Epidemiol; 2018 Jan; 33(1):67-77. PubMed ID: 29080012
[TBL] [Abstract][Full Text] [Related]
11. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Wu YL; Sequist LV; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; Yang JC
Br J Cancer; 2017 Jan; 116(2):175-185. PubMed ID: 28006816
[TBL] [Abstract][Full Text] [Related]
13. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
[TBL] [Abstract][Full Text] [Related]
14. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma.
Isaka T; Nakayama H; Yokose T; Ito H; Miyagi Y; Matsuzaki T; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Masuda M
Ann Thorac Surg; 2016 Dec; 102(6):1821-1828. PubMed ID: 27553497
[TBL] [Abstract][Full Text] [Related]
16. The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma.
Deng H; Liu J; Duan X; Liu Y
Pathol Res Pract; 2018 Mar; 214(3):450-454. PubMed ID: 29496311
[TBL] [Abstract][Full Text] [Related]
17. Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.
Pan YQ; Shi WW; Xu DP; Xu HH; Zhou MY; Yan WH
Chin Med Sci J; 2014 Sep; 29(3):156-61. PubMed ID: 25264883
[TBL] [Abstract][Full Text] [Related]
18. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
20. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]